[Clinical significance of hyaline casts in the new CKD risk classification (KDIGO 2009)]
- PMID: 23672087
[Clinical significance of hyaline casts in the new CKD risk classification (KDIGO 2009)]
Abstract
Chronic kidney disease (CKD) significantly contributes to the increased number of dialysis patients with end stage renal disease. A new CKD risk classification (KDIGO 2009) established in 2011, which is defined by albuminuria and estimated glomerular filtration rate (eGFR) values, demonstrates the relative risks of CKD in great detail. In this study, we evaluated the clinical significance of urinary casts by categorizing a risk Group 1 to 5 according to the KDIGO 2009 classification. In the high risk CKD group (risk group 3 and over), we found a significantly higher number of patients who had > 100 hyaline casts/whole field (WF) in their urine than those that had < 100 hyaline casts/WF. Further, we determined the diagnostic accuracy for the high risk CKD group when the cutoff value for the number of hyaline casts was set at > or = 100 hyaline casts/WF (sensitivity: 44.7%, specificity: 96.5%). The eGFR value was significantly lower in the group with > or = 100 hyaline casts/WF, particularly in hypertensive patients, than that in the group with < 100 hyaline casts/ WF. Of interest is that the eGFR value was significantly lower in patients with 100-999 hyaline casts/WF and > or = 1,000 hyaline casts/WF than that in patients with < 100 hyaline casts/WF in A1 stage. Thus, our present study suggests that the presence of > or = 100 hyaline casts/WF indicates decreased eGFR, and the urinary casts counting may be important and useful for the screening and early detection of high-risk CKD.
Similar articles
-
Estimation of glomerular filtration rate: does haemoglobin discriminate between ageing and true CKD?Nephrol Dial Transplant. 2009 Jun;24(6):1828-33. doi: 10.1093/ndt/gfn738. Epub 2009 Jan 8. Nephrol Dial Transplant. 2009. PMID: 19131346
-
A population-based approach for the definition of chronic kidney disease: the CKD Prognosis Consortium.J Nephrol. 2012 Jan-Feb;25(1):7-12. doi: 10.5301/jn.5000045. J Nephrol. 2012. PMID: 22038337
-
KDOQI US commentary on the 2012 KDIGO clinical practice guideline for the evaluation and management of CKD.Am J Kidney Dis. 2014 May;63(5):713-35. doi: 10.1053/j.ajkd.2014.01.416. Epub 2014 Mar 16. Am J Kidney Dis. 2014. PMID: 24647050 Review.
-
Does stage III chronic kidney disease always progress to end-stage renal disease? A ten-year follow-up study.Scand J Urol Nephrol. 2012 Jun;46(3):232-8. doi: 10.3109/00365599.2011.649045. Epub 2012 May 1. Scand J Urol Nephrol. 2012. PMID: 22545920
-
Canadian Society of Nephrology commentary on the KDIGO clinical practice guideline for CKD evaluation and management.Am J Kidney Dis. 2015 Feb;65(2):177-205. doi: 10.1053/j.ajkd.2014.10.013. Epub 2014 Nov 4. Am J Kidney Dis. 2015. PMID: 25511161 Review.
Cited by
-
Alkali supplementation as a therapeutic in chronic kidney disease: what mediates protection?Am J Physiol Renal Physiol. 2020 Dec 1;319(6):F1090-F1104. doi: 10.1152/ajprenal.00343.2020. Epub 2020 Nov 9. Am J Physiol Renal Physiol. 2020. PMID: 33166183 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous